Last update Jan. 17, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Nateglinide in other languages or writings:
Nateglinide belongs to this group or family:
Main tradenames from several countries containing Nateglinide in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a meglitinide antidiabetic. It has a different structure from the sulfonylureas, but a similar mechanism of action. It induces endogenous insulin secretion and can cause hypoglycemia.
Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients.
Oral administration, before meals, three times a day.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Its pharmacokinetic characteristics (very high plasma protein binding and a short half life) make it very unlikely its excretion into breast milk in significant amounts.
Diet, exercise, and breastfeeding improve blood sugar levels.
See below the information of this related product: